Difference between revisions of "Umbralisib (Ukoniq)"
Jump to navigation
Jump to search
m (Jwarner moved page Umbralisib (TGR-1202) to Umbralisib (Ukoniq): FDA approval with new brand name) |
m |
||
| Line 23: | Line 23: | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
| + | |||
| + | [[Category:TG Therapeutics compound]] | ||
Revision as of 13:51, 6 February 2021
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2/5/2021: Approved for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
- 2/5/2021: Approved for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq